Navigation Links
AtriCure Reports Record Second Quarter 2008 Financial Results
Date:8/5/2008

Highlights

-- Record consolidated revenues of $14.9 million

-- Record revenues from domestic MIS products - $5.1 million

-- Record international revenues of $2.3 million - 49% growth

-- Net loss improves 43% to $1.6 million

-- Secured $10 million credit facility - expands capital resources -- Reported MIS procedure times of 60 minutes and hospital stays of two

days or less

WEST CHESTER, Ohio, Aug. 5 /PRNewswire-FirstCall/ -- AtriCure, Inc. (Nasdaq: ATRC), a medical device company and a leader in cardiac surgical ablation systems, today announced record second quarter 2008 revenues of $14.9 million and record revenues for each line of business.

"Based on our encouraging financial trends, available cash and newly secured credit facility, we are well positioned to drive toward profitability," said David J. Drachman, President and Chief Executive Officer. "Importantly, minimally invasive procedure times of 60 minutes and patients discharged from the hospital at two days or less, combined with our reported clinical results are clear indicators of our progress and the large and growing opportunity for our products."

Second Quarter 2008 Financial Results

Revenues for the second quarter of 2008 were a record $14.9 million, a 20.3% increase over the second quarter of 2007 and a sequential increase of 9.8% over the first quarter of 2008. Revenues from domestic open-heart products were a record $7.4 million, an 8.9% increase over second quarter 2007 revenues of $6.8 million and a 7.2% sequential increase. Revenues from domestic minimally invasive products were a record $5.1 million, representing a
'/>"/>

SOURCE AtriCure, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. AtriCure Announces Web Cast and Conference Call of Second Quarter 2008 Financial Results
2. AtriCure Reports First Quarter 2008 Financial Results
3. AtriCure Announces Initiation of the ABLATE Pivotal Trial to Evaluate the Isolator Synergy(TM) Bipolar Ablation System to Treat Atrial Fibrillation
4. AMICAS Reports Financial Results for the Second Quarter Ended June 30, 2008
5. eResearchTechnology Reports Second Quarter 2008 Results
6. SuperGen Reports 2008 Second Quarter Financial Results
7. Neurobiological Technologies Reports Receipt of $2.1 Million Royalty Payment for Quarterly Sales of Memantine
8. InterMune Reports Second Quarter 2008 Financial Results and Business Highlights
9. CV Therapeutics Reports 2008 Second Quarter Financial Results
10. Gentiva Reports Strong Second Quarter led by Home Health Segment
11. United Therapeutics Reports Second Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Biology News(10 mins):H1N1 influenza adopted novel strategy to move from birds to humans 2H1N1 influenza adopted novel strategy to move from birds to humans 3H1N1 influenza adopted novel strategy to move from birds to humans 4Superior offspring without genetic modification 2Study finds new relationship between gene duplication and alternative splicing in plants 2Study finds new relationship between gene duplication and alternative splicing in plants 3Palomar to Commercialize FDA Cleared Over The Counter Home Use Wrinkle Treatment Laser Device Without Johnson 26amp 3B Johnson 5536 1Palomar to Commercialize FDA Cleared Over The Counter Home Use Wrinkle Treatment Laser Device Without Johnson 26amp 3B Johnson 5536 2Palomar to Commercialize FDA Cleared Over The Counter Home Use Wrinkle Treatment Laser Device Without Johnson 26amp 3B Johnson 5536 3Palomar to Commercialize FDA Cleared Over The Counter Home Use Wrinkle Treatment Laser Device Without Johnson 26amp 3B Johnson 5536 4Palomar to Commercialize FDA Cleared Over The Counter Home Use Wrinkle Treatment Laser Device Without Johnson 26amp 3B Johnson 5536 5Reportlinker Adds Global Top 10 Chemical Companies Industry Financial and SWOT Analysis 5530 1Reportlinker Adds Global Top 10 Chemical Companies Industry Financial and SWOT Analysis 5530 2Reportlinker Adds Global Top 10 Chemical Companies Industry Financial and SWOT Analysis 5530 3Reportlinker Adds Global Top 10 Chemical Companies Industry Financial and SWOT Analysis 5530 4Reportlinker Adds Global Top 10 Chemical Companies Industry Financial and SWOT Analysis 5530 5Reportlinker Adds Global Top 10 Chemical Companies Industry Financial and SWOT Analysis 5530 6Reportlinker Adds Global Top 10 Chemical Companies Industry Financial and SWOT Analysis 5530 7Reportlinker Adds Global Top 10 Chemical Companies Industry Financial and SWOT Analysis 5530 8Reportlinker Adds Global Top 10 Chemical Companies Industry Financial and SWOT Analysis 5530 9Reportlinker Adds Global Top 10 Chemical Companies Industry Financial and SWOT Analysis 5530 10Reportlinker Adds Global Top 10 Chemical Companies Industry Financial and SWOT Analysis 5530 11Reportlinker Adds Global Top 10 Chemical Companies Industry Financial and SWOT Analysis 5530 12Reportlinker Adds Global Top 10 Chemical Companies Industry Financial and SWOT Analysis 5530 13Reportlinker Adds Global Top 10 Chemical Companies Industry Financial and SWOT Analysis 5530 14Reportlinker Adds Global Top 10 Chemical Companies Industry Financial and SWOT Analysis 5530 15Reportlinker Adds Global Top 10 Chemical Companies Industry Financial and SWOT Analysis 5530 16Reportlinker Adds Global Top 10 Chemical Companies Industry Financial and SWOT Analysis 5530 17Reportlinker Adds Global Top 10 Chemical Companies Industry Financial and SWOT Analysis 5530 18Reportlinker Adds Global Top 10 Chemical Companies Industry Financial and SWOT Analysis 5530 19Reportlinker Adds Global Top 10 Chemical Companies Industry Financial and SWOT Analysis 5530 20Reportlinker Adds Global Top 10 Chemical Companies Industry Financial and SWOT Analysis 5530 21Reportlinker Adds Global Top 10 Chemical Companies Industry Financial and SWOT Analysis 5530 22Reportlinker Adds Global Top 10 Chemical Companies Industry Financial and SWOT Analysis 5530 23Reportlinker Adds Global Top 10 Chemical Companies Industry Financial and SWOT Analysis 5530 24Reportlinker Adds The Middle Eastern Pharmaceutical Market Outlook To 2014 3A Policy environment market structure competitive landscape growth oppo 5528 1Reportlinker Adds The Middle Eastern Pharmaceutical Market Outlook To 2014 3A Policy environment market structure competitive landscape growth oppo 5528 2Reportlinker Adds The Middle Eastern Pharmaceutical Market Outlook To 2014 3A Policy environment market structure competitive landscape growth oppo 5528 3Reportlinker Adds The Middle Eastern Pharmaceutical Market Outlook To 2014 3A Policy environment market structure competitive landscape growth oppo 5528 4Reportlinker Adds The Middle Eastern Pharmaceutical Market Outlook To 2014 3A Policy environment market structure competitive landscape growth oppo 5528 5Reportlinker Adds The Middle Eastern Pharmaceutical Market Outlook To 2014 3A Policy environment market structure competitive landscape growth oppo 5528 6Reportlinker Adds The Middle Eastern Pharmaceutical Market Outlook To 2014 3A Policy environment market structure competitive landscape growth oppo 5528 7Reportlinker Adds The Middle Eastern Pharmaceutical Market Outlook To 2014 3A Policy environment market structure competitive landscape growth oppo 5528 8Reportlinker Adds The Middle Eastern Pharmaceutical Market Outlook To 2014 3A Policy environment market structure competitive landscape growth oppo 5528 9Reportlinker Adds The Middle Eastern Pharmaceutical Market Outlook To 2014 3A Policy environment market structure competitive landscape growth oppo 5528 10Reportlinker Adds The Middle Eastern Pharmaceutical Market Outlook To 2014 3A Policy environment market structure competitive landscape growth oppo 5528 11